| Autor: |
Edgar V. Lerma, Mark E. Bensink, Kamlesh M. Thakker, Richard Lieblich, Martin Bunke, Andrew Rava, Kaijun Wang, Michael V. Murphy, David Oliveri, Diana T. Amari, David M.W. Cork, Juan Carlos Q. Velez |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Kidney Medicine, Vol 5, Iss 9, Pp 100693- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0595 |
| DOI: |
10.1016/j.xkme.2023.100693 |
| Popis: |
Rationale & Objective: Among patients with IgA nephropathy (IgAN), proteinuria and decline in kidney function may be associated with increased economic burden. This study aimed to provide current information on the epidemiology and economic burden of IgAN in the United States. Study Design: Retrospective cohort study. Setting & Study Population: Overall, 9,984 patients in the Optum’s Market Clarity database identified by the presence of at least 2 natural language processing-derived IgAN signs and disease and symptoms terms; 813 with linked claims data included in a health care resource utilization/cost subcohort. Predictor: High-risk proteinuria (≥1 g/d), chronic kidney disease (CKD) stage. Outcomes: Standardized prevalence, health care resource utilization, costs. Analytical Approach: Descriptive statistics for categorical and continuous variables. Direct standardization for prevalence estimation. Generalized linear models for health care resource utilization/costs, reported as per-patient-per-month (PPPM) costs in 2020 US dollars. Results: The estimated standardized US prevalence of IgAN (2016-2020) was 329.0 per 1,000,000 persons. High-risk proteinuria (≥1 vs |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
